131 related articles for article (PubMed ID: 15989575)
21. Time-dependent inhibition of protein farnesyltransferase by a benzodiazepine peptide mimetic.
Roskoski R; Ritchie PA
Biochemistry; 2001 Aug; 40(31):9329-35. PubMed ID: 11478901
[TBL] [Abstract][Full Text] [Related]
22. Protein Prenyltransferases and Their Inhibitors: Structural and Functional Characterization.
Marchwicka A; Kamińska D; Monirialamdari M; Błażewska KM; Gendaszewska-Darmach E
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628237
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy.
Sebti SM; Hamilton AD
Pharmacol Ther; 1997; 74(1):103-14. PubMed ID: 9336018
[TBL] [Abstract][Full Text] [Related]
24. Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
deSolms SJ; Ciccarone TM; MacTough SC; Shaw AW; Buser CA; Ellis-Hutchings M; Fernandes C; Hamilton KA; Huber HE; Kohl NE; Lobell RB; Robinson RG; Tsou NN; Walsh ES; Graham SL; Beese LS; Taylor JS
J Med Chem; 2003 Jul; 46(14):2973-84. PubMed ID: 12825937
[TBL] [Abstract][Full Text] [Related]
25. Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents.
Minutolo F; Asso V; Bertini S; Betti L; Ciriaco M; Danesi R; Gervasi G; Ghilardi E; Giovanetti E; Giannaccini G; Placanica G; Prota G; Rapposelli S; Macchia M
Med Chem; 2005 May; 1(3):239-44. PubMed ID: 16787319
[TBL] [Abstract][Full Text] [Related]
26. A Homology Based Model and Virtual Screening of Inhibitors for Human Geranylgeranyl Transferase 1 (GGTase1).
Thippanna M; Subramani PA; Lomada D; Narala VR; Reddy MC
Bioinformation; 2013; 9(19):973-7. PubMed ID: 24391360
[TBL] [Abstract][Full Text] [Related]
27. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
[TBL] [Abstract][Full Text] [Related]
28. Protein farnesyltransferase inhibitors.
Ayral-Kaloustian S; Salaski EJ
Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
[TBL] [Abstract][Full Text] [Related]
29. Dominant negative alpha-subunit of FTase inhibits effects of insulin and IGF-I in MCF-7 cells.
Solomon CS; Goalstone ML
Biochem Biophys Res Commun; 2002 Mar; 291(3):458-65. PubMed ID: 11855811
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
Lerner EC; Hamilton AD; Sebti SM
Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
[TBL] [Abstract][Full Text] [Related]
31. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
32. Conversion of protein farnesyltransferase to a geranylgeranyltransferase.
Terry KL; Casey PJ; Beese LS
Biochemistry; 2006 Aug; 45(32):9746-55. PubMed ID: 16893176
[TBL] [Abstract][Full Text] [Related]
33. Farnesyltransferase as a target for anticancer drug design.
Qian Y; Sebti SM; Hamilton AD
Biopolymers; 1997; 43(1):25-41. PubMed ID: 9174410
[TBL] [Abstract][Full Text] [Related]
34. Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes.
Lee R; Chang SY; Trinh H; Tu Y; White AC; Davies BS; Bergo MO; Fong LG; Lowry WE; Young SG
Hum Mol Genet; 2010 Apr; 19(8):1603-17. PubMed ID: 20106865
[TBL] [Abstract][Full Text] [Related]
35. Protein farnesyltransferase and adenosine receptors.
Robins P
IDrugs; 1998 May; 1(1):6-7. PubMed ID: 18465490
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of chronically active ras: potential for treatment of human malignancies.
Blum R; Cox AD; Kloog Y
Recent Pat Anticancer Drug Discov; 2008 Jan; 3(1):31-47. PubMed ID: 18289122
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells.
Virtanen SS; Sandholm J; Yegutkin G; Kalervo Väänänen H; Härkönen PL
Cell Biol Int; 2010 Aug; 34(8):815-26. PubMed ID: 20446922
[TBL] [Abstract][Full Text] [Related]
38. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
Sun J; Ohkanda J; Coppola D; Yin H; Kothare M; Busciglio B; Hamilton AD; Sebti SM
Cancer Res; 2003 Dec; 63(24):8922-9. PubMed ID: 14695209
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
[TBL] [Abstract][Full Text] [Related]
40. Development of selective, potent RabGGTase inhibitors.
Stigter EA; Guo Z; Bon RS; Wu YW; Choidas A; Wolf A; Menninger S; Waldmann H; Blankenfeldt W; Goody RS
J Med Chem; 2012 Oct; 55(19):8330-40. PubMed ID: 22963166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
